Guosheng Yin

List of Publications by Year
in descending order

144 papers	3,960 citations	136950 32 h-index	144013 57 g-index
157 all docs	157 docs citations	157 times ranked	3767 citing authors

#	Article	IF	Citations
1	ErbB2 Increases Vascular Endothelial Growth Factor Protein Synthesis via Activation of Mammalian Target of Rapamycin/p70S6K Leading to Increased Angiogenesis and Spontaneous Metastasis of Human Breast Cancer Cells. Cancer Research, 2006, 66, 2028-2037.	0.9	182
2	Root Canal Filled Versus Non-Root Canal Filled Teeth: A Retrospective Comparison of Survival Times. Journal of Public Health Dentistry, 2005, 65, 90-96.	1.2	164
3	HER Family Receptor Abnormalities in Lung Cancer Brain Metastases and Corresponding Primary Tumors. Clinical Cancer Research, 2009, 15, 4829-4837.	7.0	151
4	Bayesian Dose-Finding in Phase I/II Clinical Trials Using Toxicity and Efficacy Odds Ratios. Biometrics, 2006, 62, 777-787.	1.4	142
5	Bayesian Model Averaging Continual Reassessment Method in Phase I Clinical Trials. Journal of the American Statistical Association, 2009, 104, 954-968.	3.1	142
6	Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. Cancer, 2006, 107, 1348-1354.	4.1	140
7	Cure rate models: A unified approach. Canadian Journal of Statistics, 2005, 33, 559-570.	0.9	125
8	Bayesian Dose Finding in Oncology For Drug Combinations by Copula Regression. Journal of the Royal Statistical Society Series C: Applied Statistics, 2009, 58, 211-224.	1.0	124
9	Sex Determining Region Y-Box 2 (SOX2) Is a Potential Cell-Lineage Gene Highly Expressed in the Pathogenesis of Squamous Cell Carcinomas of the Lung. PLoS ONE, 2010, 5, e9112.	2.5	117
10	Bayesian Quantile Regression for Longitudinal Studies with Nonignorable Missing Data. Biometrics, 2010, 66, 105-114.	1.4	102
11	Semiparametric Transformation Models for Survival Data With a Cure Fraction. Journal of the American Statistical Association, 2006, 101, 670-684.	3.1	101
12	A Latent Contingency Table Approach to Dose Finding for Combinations of Two Agents. Biometrics, 2009, 65, 866-875.	1.4	98
13	Phase 3 study comparing the use of docetaxel on an every‐3‐week versus weekly schedule in the treatment of metastatic breast cancer. Cancer, 2008, 112, 1455-1461.	4.1	94
14	Upregulation and activation of PKCα by ErbB2 through Src promotes breast cancer cell invasion that can be blocked by combined treatment with PKCα and Src inhibitors. Oncogene, 2006, 25, 3286-3295.	5.9	90
15	Bayesian Dose Finding by Jointly Modelling Toxicity and Efficacy as Time-to-Event Outcomes. Journal of the Royal Statistical Society Series C: Applied Statistics, 2009, 58, 719-736.	1.0	81
16	Sequential continual reassessment method for two‐dimensional dose finding. Statistics in Medicine, 2008, 27, 5664-5678.	1.6	72
17	Bayesian optimal interval design for dose finding in drug-combination trials. Statistical Methods in Medical Research, 2017, 26, 2155-2167.	1.5	69
18	Conditional quantile screening in ultrahigh-dimensional heterogeneous data. Biometrika, 2015, 102, 65-76.	2.4	66

#	ARTICLE	IF	CITATIONS
19	Methylation of the candidate biomarker *TCF21* is very frequent across a spectrum of early-stage nonsmall cell lung cancers. Cancer, 2011, 117, 606-617.	4.1	59
20	Bayesian data augmentation dose finding with continual reassessment method and delayed toxicity. Annals of Applied Statistics, 2013, 7, 1837-2457.	1.1	58
21	Phase II Trial Design with Bayesian Adaptive Randomization and Predictive Probability. Journal of the Royal Statistical Society Series C: Applied Statistics, 2012, 61, 219-235.	1.0	57
22	Bayesian phase I/II adaptively randomized oncology trials with combined drugs. Annals of Applied Statistics, 2011, 5, 924-942.	1.1	56
23	Worth Adapting? Revisiting the Usefulness of Outcome-Adaptive Randomization. Clinical Cancer Research, 2012, 18, 4498-4507.	7.0	56
24	Using the Restricted Mean Survival Time Difference as an Alternative to the Hazard Ratio for Analyzing Clinical Cardiovascular Studies. Circulation, 2019, 140, 1366-1368.	1.6	56
25	Robust EM Continual Reassessment Method in Oncology Dose Finding. Journal of the American Statistical Association, 2011, 106, 818-831.	3.1	54
26	Additive hazards model with multivariate failure time data. Biometrika, 2004, 91, 801-818.	2.4	51
27	Outlier detection for high-dimensional data. Biometrika, 2015, 102, 589-599.	2.4	51
28	Inter-Ethnic/Racial Facial Variations: A Systematic Review and Bayesian Meta-Analysis of Photogrammetric Studies. PLoS ONE, 2015, 10, e0134525.	2.5	48
29	Maximum Likelihood Estimation for the Proportional Odds Model With Random Effects. Journal of the American Statistical Association, 2005, 100, 470-483.	3.1	43
30	STEIN: A simple toxicity and efficacy interval design for seamless phase I/II clinical trials. Statistics in Medicine, 2017, 36, 4106-4120.	1.6	41
31	Quantile Regression Models with Multivariate Failure Time Data. Biometrics, 2005, 61, 151-161.	1.4	40
32	Marginal Analysis of Correlated Failure Time Data with Informative Cluster Sizes. Biometrics, 2007, 63, 663-672.	1.4	38
33	Bayesian generalized method of moments. Bayesian Analysis, 2009, 4, .	3.0	38
34	Comparison of Transmissibility of Coronavirus Between Symptomatic and Asymptomatic Patients: Reanalysis of the Ningbo COVID-19 Data. JMIR Public Health and Surveillance, 2020, 6, e19464.	2.6	37
35	A General Class of Bayesian Survival Models with Zero and Nonzero Cure Fractions. Biometrics, 2005, 61, 403-412.	1.4	33
36	Bayesian randomized clinical trials: From fixed to adaptive design. Contemporary Clinical Trials, 2017, 59, 77-86.	1.8	33

#	ARTICLE	IF	CITATIONS
37	Bayesian two-step Lasso strategy for biomarker selection in personalized medicine development for time-to-event endpoints. Contemporary Clinical Trials, 2013, 36, 642-650.	1.8	31
38	Escalation with overdose control for phase I drug‑combination trials. Statistics in Medicine, 2013, 32, 4400-4412.	1.6	30
39	Bayesian Cure Rate Frailty Models with Application to a Root Canal Therapy Study. Biometrics, 2005, 61, 552-558.	1.4	29
40	Power-Transformed Linear Quantile Regression With Censored Data. Journal of the American Statistical Association, 2008, 103, 1214-1224.	3.1	29
41	Phase III Randomized Trial of Dose Intensive Neoadjuvant Chemotherapy with or Without G‑CSF in Locally Advanced Breast Cancer: Long‑Term Results. Oncologist, 2011, 16, 1527-1534.	3.7	29
42	Comparison of Ductal Lavage and Random Periareolar Fine Needle Aspiration as Tissue Acquisition Methods in Early Breast Cancer Prevention Trials. Clinical Cancer Research, 2007, 13, 4943-4948.	7.0	27
43	Efficacy of COVID-19 Treatments: A Bayesian Network Meta-Analysis of Randomized Controlled Trials. Frontiers in Public Health, 2021, 9, 729559.	2.7	27
44	A Class of Bayesian Shared Gamma Frailty Models with Multivariate Failure Time Data. Biometrics, 2005, 61, 208-216.	1.4	26
45	Correlation of cytologic findings and chromosomal instability detected by fluorescence in situ hybridization in breast fine-needle aspiration specimens from women at high risk for breast cancer. Modern Pathology, 2006, 19, 622-629.	5.5	25
46	Semiparametric median residual life model and inference. Canadian Journal of Statistics, 2010, 38, 665-679.	0.9	24
47	Glutathione-S-Transferase-Pi Expression in Early Breast Cancer: Association With Outcome and Response to Chemotherapy. Cancer Investigation, 2010, 28, 554-559.	1.3	24
48	Detecting Overall Survival Benefit Derived From Survival Postprogression Rather Than Progression-Free Survival. Journal of the National Cancer Institute, 2015, 107, .	6.3	24
49	Nonparametric overdose control with late-onset toxicity in phase I clinical trials. Biostatistics, 2017, 18, 180-194.	1.5	23
50	Cure Rate Model With Mismeasured Covariates Under Transformation. Journal of the American Statistical Association, 2008, 103, 743-756.	3.1	22
51	Novel Clinical Trial Designs for Treatment of Ductal Carcinoma In Situ of the Breast with Trastuzumab (Herceptin). Breast Journal, 2007, 13, 72-75.	1.0	21
52	The global, regional, and national burden of cancer among adolescents and young adults in 204 countries and territories, 1990‑2019: a population-based study. Journal of Hematology and Oncology, 2021, 14, 89.	17.0	21
53	Cure Rate Quantile Regression for Censored Data With a Survival Fraction. Journal of the American Statistical Association, 2013, 108, 1517-1531.	3.1	19
54	Trends and Patterns of Disparities in Burden of Lung Cancer in the United States, 1974-2015. Frontiers in Oncology, 2019, 9, 404.	2.8	19

#	ARTICLE	IF	CITATIONS
55	Reconnecting *p*-Value and Posterior Probability Under One- and Two-Sided Tests. American Statistician, 2021, 75, 265-275.	1.6	19
56	Bayesian transformation cure frailty models with multivariate failure time data. Statistics in Medicine, 2008, 27, 5929-5940.	1.6	18
57	Fractional Dose-Finding Methods with Late-Onset Toxicity in Phase I Clinical Trials. Journal of Biopharmaceutical Statistics, 2013, 23, 856-870.	0.8	18
58	Smoothed and Corrected Score Approach to Censored Quantile Regression With Measurement Errors. Journal of the American Statistical Association, 2015, 110, 1670-1683.	3.1	18
59	Interleukin-11 Receptor Is a Candidate Target for Ligand-Directed Therapy in Lung Cancer. American Journal of Pathology, 2016, 186, 2162-2170.	3.8	18
60	Partially Linear Additive Hazards Regression With Varying Coefficients. Journal of the American Statistical Association, 2008, 103, 1200-1213.	3.1	17
61	Dose-Response Curve Estimation: A Semiparametric Mixture Approach. Biometrics, 2011, 67, 1543-1554.	1.4	17
62	Bayesian hybrid dose–finding design in phase I oncology clinical trials. Statistics in Medicine, 2011, 30, 2098-2108.	1.6	17
63	Inference for a Class of Transformed Hazards Models. Journal of the American Statistical Association, 2005, 100, 1000-1008.	3.1	16
64	Censored cumulative residual independent screening for ultrahigh-dimensional survival data. Lifetime Data Analysis, 2018, 24, 273-292.	0.9	16
65	Self-Designing Trial Combined with Classical Group Sequential Monitoring. Journal of Biopharmaceutical Statistics, 2005, 15, 667-675.	0.8	14
66	Generalized method of moments estimation for linear regression with clustered failure time data. Biometrika, 2009, 96, 293-306.	2.4	14
67	Comments on â€˜Competing designs for drug combination in phase I dose–finding clinical trialsâ€™ by Mâ€K. Riviere, F. Dubois, and S. Zohar. Statistics in Medicine, 2015, 34, 13-17.	1.6	14
68	Bayes factor and posterior probability: Complementary statistical evidence to p-value. Contemporary Clinical Trials, 2015, 44, 33-35.	1.8	14
69	Model checking for additive hazards model with multivariate survival data. Journal of Multivariate Analysis, 2007, 98, 1018-1032.	1.0	13
70	Bayesian Semiparametric Cure Rate Model with an Unknown Threshold. Scandinavian Journal of Statistics, 2008, 35, 540-556.	1.4	13
71	Twoâ€stage dose finding for cytostatic agents in phase I oncology trials. Statistics in Medicine, 2013, 32, 644-660.	1.6	12
72	A general transformation class of semiparametric cure rate frailty models. Annals of the Institute of Statistical Mathematics, 2012, 64, 959-989.	0.8	11

#	Article	IF	Citations
73	Ensemble Approaches to Estimating the Population Mean with Missing Response. Scandinavian Journal of Statistics, 2017, 44, 899-917.	1.4	11
74	Landmark cure rate models with time-dependent covariates. Statistical Methods in Medical Research, 2017, 26, 2042-2054.	1.5	11
75	Adaptive Design and Estimation in Randomized Clinical Trials with Correlated Observations. Biometrics, 2005, 61, 362-369.	1.4	10
76	Boosting conditional logit model. Journal of Choice Modelling, 2018, 26, 48-63.	2.3	10
77	The Delaunay triangulation learner and its ensembles. Computational Statistics and Data Analysis, 2020, 152, 107030.	1.2	10
78	Bayesian phase II adaptive randomization by jointly modeling time-to-event efficacy and binary toxicity. Lifetime Data Analysis, 2011, 17, 156-174.	0.9	9
79	Stochastic Generalized Method of Moments. Journal of Computational and Graphical Statistics, 2011, 20, 714-727.	1.7	9
80	Pearson-type goodness-of-fit test with bootstrap maximum likelihood estimation. Electronic Journal of Statistics, 2013, 7, 412-427.	0.7	9
81	Bayesian Enhancement Two-Stage Design for Single-Arm Phase II Clinical Trials with Binary and Time-to-Event Endpoints. Biometrics, 2018, 74, 1055-1064.	1.4	9
82	Uniformly most powerful Bayesian interval design for phase I dose–finding trials. Pharmaceutical Statistics, 2018, 17, 710-724.	1.3	9
83	Bayesian Two-Stage Design for Phase II Clinical Trials with Switching Hypothesis Tests. Bayesian Analysis, 2017, 12, .	3.0	9
84	C-index regression for recurrent event data. Contemporary Clinical Trials, 2022, 118, 106787.	1.8	9
85	Bootstrap aggregating continual reassessment method for dose finding in drug-combination trials. Annals of Applied Statistics, 2016, 10, .	1.1	8
86	Functional Censored Quantile Regression. Journal of the American Statistical Association, 2020, 115, 931-944.	3.1	8
87	Efficiency improvement in a class of survival models through model-free covariate incorporation. Lifetime Data Analysis, 2011, 17, 552-565.	0.9	7
88	Phase I trial design for drug combinations with Bayesian model averaging. Pharmaceutical Statistics, 2015, 14, 108-119.	1.3	7
89	Multiple Imputation for Cure Rate Quantile Regression with Censored Data. Biometrics, 2017, 73, 94-103.	1.4	7
90	Bayesian Adaptive Randomization and Trial Monitoring with Predictive Probability for Time-to-Event Endpoint. Statistics in Biosciences, 2018, 10, 420-438.	1.2	7

#	ARTICLE	IF	CITATIONS
91	An alternative approach for estimating the number needed to treat for survival endpoints. PLoS ONE, 2019, 14, e0223301.	2.5	7
92	Unit information prior for adaptive information borrowing from multiple historical datasets. Statistics in Medicine, 2021, 40, 5657-5672.	1.6	7
93	Bayesian adaptive model selection design for optimal biological dose finding in phase I/II clinical trials. Biostatistics, 2023, 24, 277-294.	1.5	7
94	Efficient Algorithm for Computing Maximum Likelihood Estimates in Linear Transformation Models. Journal of Computational and Graphical Statistics, 2006, 15, 228-245.	1.7	6
95	Two-stage adaptive randomization for delayed response in clinical trials. Journal of the Royal Statistical Society Series C: Applied Statistics, 2014, 63, 559-578.	1.0	6
96	Partitioned log-rank tests for the overall homogeneity of hazard rate functions. Lifetime Data Analysis, 2017, 23, 400-425.	0.9	6
97	Nonâ€parametric overdose control for dose finding in drug combination trials. Journal of the Royal Statistical Society Series C: Applied Statistics, 2019, 68, 1111-1130.	1.0	6
98	Restricted mean survival time for intervalâ€censored data. Statistics in Medicine, 2020, 39, 3879-3895.	1.6	6
99	Bayesian Hierarchical Modeling and Biomarker Cutoff Identification in Basket Trials. Statistics in Biopharmaceutical Research, 2021, 13, 248-258.	0.8	6
100	Dynamic portfolio choice without cash. Quantitative Finance, 2019, 19, 313-326.	1.7	5
101	Multiple change-points detection in high dimension. Random Matrices: Theory and Application, 2019, 08, 1950014.	1.1	5
102	Two Simulation Methods for Constructing Confidence Bands Under the Additive Risk Model. Journal of Biopharmaceutical Statistics, 2004, 14, 389-402.	0.8	4
103	Local likelihood with timeâ€varying additive hazards model. Canadian Journal of Statistics, 2007, 35, 321-337.	0.9	4
104	Bayesian goodness-of-fit test for censored data. Journal of Statistical Planning and Inference, 2009, 139, 1474-1483.	0.6	4
105	Maximum likelihood estimation for incomplete multinomial data via the weaver algorithm. Statistics and Computing, 2018, 28, 1095-1117.	1.5	4
106	Two-stage seamless transition design from open-label single-arm to randomized double-arm clinical trials. Statistical Methods in Medical Research, 2018, 27, 158-171.	1.5	4
107	Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura. New England Journal of Medicine, 2019, 380, e32.	27.0	4
108	Fractional design: An alternative paradigm for late-onset toxicities in oncology dose-finding studies. Contemporary Clinical Trials Communications, 2020, 19, 100650.	1.1	4

#	Article	IF	Citations
109	Adaptive iterative Hessian sketch via A-optimal subsampling. Statistics and Computing, 2020, 30, 1075-1090.	1.5	4
110	Generalized Method of Moments for Additive Hazards Model with Clustered Dental Survival Data. Scandinavian Journal of Statistics, 2016, 43, 1124-1139.	1.4	3
111	Biostatistics pitfalls: Lessons learned from analysis of medical data. Contemporary Clinical Trials, 2019, 87, 105875.	1.8	3
112	START: single-to-double arm transition design for phase II clinical trials. Pharmaceutical Statistics, 2020, 19, 454-467.	1.3	3
113	Concordance index: Surrogacy of progression-free survival for overall survival. Contemporary Clinical Trials, 2021, 104, 106353.	1.8	3
114	Bayesian Hierarchical Model for Change Point Detection in Multivariate Sequences. Technometrics, 2022, 64, 177-186.	1.9	3
115	Statistical Issues and Lessons Learned From COVID-19 Clinical Trials With Lopinavir-Ritonavir and Remdesivir. JMIR Public Health and Surveillance, 2020, 6, e19538.	2.6	3
116	CFO: Calibration-free odds design for phase I/II clinical trials. Statistical Methods in Medical Research, 2022, 31, 1051-1066.	1.5	3
117	Bayesian Two-Stage Dose Finding for Cytostatic Agents Via Model Adaptation. Journal of the Royal Statistical Society Series C: Applied Statistics, 2016, 65, 465-482.	1.0	2
118	Cure rate quantile regression accommodating both finite and infinite survival times. Canadian Journal of Statistics, 2017, 45, 29-43.	0.9	2
119	Radical Surgery or Watchful Waiting in Prostate Cancer. New England Journal of Medicine, 2019, 380, 1083-1084.	27.0	2
120	Bayesian enhancement two-stage design with error control for phase II clinical trials. Statistics in Medicine, 2020, 39, 4452-4465.	1.6	2
121	Pair Chart Test for an Early Survival Difference. Lifetime Data Analysis, 2005, 11, 117-129.	0.9	1
122	Least squares estimation of varying-coefficient hazard regression with application to breast cancer dose-intensity data. Canadian Journal of Statistics, 2009, 37, 659-674.	0.9	1
123	Generalized partially linear single-index model for zero-inflated count data. Statistics in Medicine, 2015, 34, 876-886.	1.6	1
124	Power computation for hypothesis testing with high-dimensional covariance matrices. Computational Statistics and Data Analysis, 2016, 104, 10-23.	1.2	1
125	Varying-association copula models for multivariate survival data. Canadian Journal of Statistics, 2018, 46, 556-576.	0.9	1
126	Reduction in number to treat versus number needed to treat. BMC Medical Research Methodology, 2021, 21, 48.	3.1	1

#	ARTICLE	IF	CITATIONS
127	Response-Adaptive Rerandomization. Journal of the Royal Statistical Society Series C: Applied Statistics, 2021, 70, 1281-1298.	1.0	1
128	Reconstructing the Kaplan–Meier Estimator as an M-estimator. American Statistician, 0, , 1-14.	1.6	1
129	Demystify Lindley's paradox by connecting p-value and posterior probability. Statistics and Its Interface, 2021, 14, 489-502.	0.3	1
130	Principles and Reporting of Bayesian Trials. Journal of Thoracic Oncology, 2021, 16, 30-36.	1.1	1
131	Bayesian cure rate model accommodating multiplicative and additive covariates. Statistics and Its Interface, 2009, 2, 513-521.	0.3	1
132	Coarse-To-Fine Framework For Music Generation via Generative Adversarial Networks. , 2020, , .		1
133	A variable selection approach to multiple change-points detection with ordinal data. Statistics and Its Interface, 2020, 13, 251-260.	0.3	1
134	Random Walk and Parallel Crossing Bayesian Optimal Interval Design for Dose Finding with Combined Drugs. , 2017, , 21-35.		0
135	AVERAGE HOLDING PRICE. Annals of Financial Economics, 2018, 13, 1850002.	1.4	0
136	Design of Noninferiority Trials for Hypofractionated vs Conventional Radiotherapy Among Patients With Cancer. JAMA Oncology, 2019, 5, 1508.	7.1	0
137	Reanalysis of Data Comparing Prophylactic Cranial Irradiation vs Observation in Patients With Locally Advanced Non–Small Cell Lung Cancer. JAMA Oncology, 2019, 5, 1638.	7.1	0
138	Convergence rates of the blocked Gibbs sampler with random scan in the Wasserstein metric. Stochastics, 2020, 92, 265-274.	1.1	0
139	Dynamic ordering design for dose finding in drug–combination trials. Pharmaceutical Statistics, 2021, 20, 348-361.	1.3	0
140	Sample size re-estimation in adaptive enrichment design. Contemporary Clinical Trials, 2021, 100, 106216.	1.8	0
141	Testing overall and subpopulation treatment effects with measurement errors. Statistica Sinica, 2013, 23, 1019-1042.	0.3	0
142	Ventilation prediction for ICU patients with LSTM-based deep relative risk model. , 2020, , .		0
143	Bayesian Nonparametric Analysis of Restricted Mean Survival Time. Biometrics, 2023, 79, 1383-1396.	1.4	0
144	Triangular Concordance Learning of Networks. Journal of Computational and Graphical Statistics, 0, , 1-32.	1.7	0